UBS Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-853,600
| Closed | -$104M | – | 11246 |
|
|
2025
Q4 | $104M | Buy |
853,600
+293,200
| +52% | +$33.6M | 0.02% | 990 |
|
|
2025
Q3 | $56.2M | Buy |
560,400
+143,500
| +34% | +$12.9M | 0.01% | 1511 |
|
|
2025
Q2 | $34.6M | Buy |
416,900
+312,500
| +299% | +$24.9M | 0.01% | 1854 |
|
|
2025
Q1 | $8.47M | Sell |
104,400
-390,600
| -79% | -$34.9M | ﹤0.01% | 3227 |
|
|
2024
Q4 | $44.6M | Sell |
495,000
-1,625,000
| -77% | -$157M | 0.01% | 1568 |
|
|
2024
Q3 | $209M | Buy |
2,120,000
+1,210,000
| +133% | +$119M | 0.05% | 390 |
|
|
2024
Q2 | $84.4M | Buy |
910,000
+103,800
| +13% | +$9.31M | 0.02% | 725 |
|
|
2024
Q1 | $76.5M | Sell |
806,200
-1,042,000
| -56% | -$96.7M | 0.02% | 786 |
|
|
2023
Q4 | $165M | Buy |
1,848,200
+415,000
| +29% | +$30.8M | 0.05% | 375 |
|
|
2023
Q3 | $105M | Buy |
1,433,200
+86,575
| +6% | +$6.92M | 0.04% | 487 |
|
|
2023
Q2 | $112M | Buy |
1,346,625
+722,325
| +116% | +$60.4M | 0.04% | 449 |
|
|
2023
Q1 | $47.6M | Buy |
624,300
+109,311
| +21% | +$9.07M | 0.02% | 807 |
|
|
2022
Q4 | $42.7M | Sell |
514,989
-115,011
| -18% | -$9.31M | 0.02% | 902 |
|
|
2022
Q3 | $50M | Buy |
630,000
+205,000
| +48% | +$17.3M | 0.02% | 689 |
|
|
2022
Q2 | $31.6M | Sell |
425,000
-1,233,200
| -74% | -$92.6M | 0.01% | 1035 |
|
|
2022
Q1 | $149M | Buy |
1,658,200
+852,660
| +106% | +$78.7M | 0.05% | 386 |
|
|
2021
Q4 | $90.2M | Buy |
805,540
+654,540
| +433% | +$78.9M | 0.03% | 648 |
|
|
2021
Q3 | $19M | Buy |
+151,000
| New | +$19.4M | 0.01% | 1539 |
|
|
2021
Q2 | – | Sell |
-195,200
| Closed | -$26.5M | – | 9877 |
|
|
2021
Q1 | $26.5M | Buy |
195,200
+101,400
| +108% | +$15.2M | 0.01% | 1252 |
|
|
2020
Q4 | $13.2M | Buy |
+93,800
| New | +$12M | ﹤0.01% | 1636 |
|
|
2020
Q1 | – | Sell |
-87,500
| Closed | -$8.32M | – | 8479 |
|
|
2019
Q4 | $8.32M | Sell |
87,500
-97,200
| -53% | -$8.41M | ﹤0.01% | 2121 |
|
|
2019
Q3 | $14.1M | Sell |
184,700
-92,800
| -33% | -$7.71M | 0.01% | 1490 |
|
|
2019
Q2 | $24.3M | Sell |
277,500
-1,340,000
| -83% | -$114M | 0.01% | 1078 |
|
|
2019
Q1 | $146M | Buy |
1,617,500
+1,591,600
| +6,145% | +$135M | 0.06% | 286 |
|
|
2018
Q4 | $1.86M | Buy |
25,900
+25,100
| +3,138% | +$2.02M | ﹤0.01% | 3114 |
|
|
2018
Q3 | $77K | Sell |
800
-549,200
| -100% | -$53.2M | ﹤0.01% | 5807 |
|
|
2018
Q2 | $52.4M | Buy |
+550,000
| New | +$50.5M | 0.02% | 632 |
|
|
2017
Q2 | – | Sell |
-796,300
| Closed | -$55.2M | – | 8028 |
|
|
2017
Q1 | $55.2M | Buy |
796,300
+319,800
| +67% | +$21.5M | 0.03% | 517 |
|
|
2016
Q4 | $28.2M | Buy |
476,500
+468,500
| +5,856% | +$28.9M | 0.02% | 816 |
|
|
2016
Q3 | $530K | Sell |
8,000
-52,500
| -87% | -$3.25M | ﹤0.01% | 3885 |
|
|
2016
Q2 | $3.27M | Buy |
60,500
+20,500
| +51% | +$1.12M | ﹤0.01% | 2361 |
|
|
2016
Q1 | $2.07M | Buy |
40,000
+39,700
| +13,233% | +$2.06M | ﹤0.01% | 2647 |
|
|
2015
Q4 | $21K | Hold |
300
| – | – | ﹤0.01% | 6723 |
|
|
2015
Q3 | $19K | Hold |
300
| – | – | ﹤0.01% | 6754 |
|
|
2015
Q2 | $25K | Hold |
300
| – | – | ﹤0.01% | 6671 |
|
|
2015
Q1 | $23K | Sell |
300
-900
| -75% | -$62.9K | ﹤0.01% | 6860 |
|
|
2014
Q4 | $75K | Buy |
+1,200
| New | +$68.4K | ﹤0.01% | 6002 |
|
Other funds holding XBI
JFG
UBS Group's XBI Position: Q1 2026 in Review
UBS Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 19% in Q1 2026, buying an estimated $71.1M and bringing the position to 3,546,650 shares worth $453M. The position accounts for 0.07% of the portfolio, ranked #291.
UBS Group first reported a position in XBI in Q4 2014 and has held it in 46 quarters since. The position peaked at $738M in Q1 2019. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- UBS Group held 3,546,650 shares of State Street SPDR S&P Biotech ETF worth $453M as of Q1 2026.
- UBS Group bought 569,529 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $71.1M.
- State Street SPDR S&P Biotech ETF made up 0.07% of UBS Group's portfolio in Q1 2026, its #291 holding.
- UBS Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2014 and has held it in 46 quarters since.
- UBS Group's State Street SPDR S&P Biotech ETF position peaked at $738M in Q1 2019.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.